Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P350. The effect of infliximab therapy on nutritional status in patients with Crohn's disease
Authors:

T. Yamamoto1, M. Shiraki1, S. Umegae1, K. Matsumoto1, 1Yokkaichi Social Insurance Hospital, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P350

Mucosal and histologic response to cyclosporin in ulcerative colitis: a cohort study

Authors:

C. Fron1, G. Belleannée2, E. Chabrun3, F. Poullenot1, C. Subtil1, F. Zerbib3, M. Capdepont1, D. Laharie*1

1CHU de Bordeaux, Gastroenterologie, Pessac, France, 2CHU de Bordeaux, Pathologie, Pessac, France, 3CHU de Bordeaux, Gastroenterologie, Bordeaux, France

P351.

Screening for opportunistic infection prior to initiating immunomodulator therapy in IBD patients – Practice in the North East of England

Authors:

S. Nair, D. Hobday, Sunderland Royal Hospital, Gastroenterology, Sunderland, United Kingdom

P351. Gender impact on the clinical presentation of the newly diagnosed, pediatric-onset Crohn's disease: A single center registry-based study
P351. Long term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn's disease: In the era of biologics can steroids be reconsidered?
P351. The effect of infliximab pre-treated human blood-enriched dendritic cells from patients with active Crohn's disease and healthy controls on subsequent human T-lymphocyte phenotype and cytokine production in vitro
Authors:

S. Peake1, D. Bernardo2, E. Mann2, J. Landy1, H. Omar2, S. Knight2, A. Hart1, 1St Mark's Hospital, IBD Unit, Harrow, United Kingdom, 2Imperial College, APRG, London, United Kingdom

P351

Does failure to respond to one anti-TNF agent in Ulcerative Colitis predict treatment failure with other anti-TNF agents?

Authors:

F. AlAlawi*, D. Keegan, K. Byrne, H. Mulcahy, G. Cullen, G. Doherty

Centre for Colorectal Disease, St Vincent’s University Hospital & School of Medicine and Medical Science, University College Dublin, Gastroenterology, Dublin, Ireland

P352.

Screening for melanoma and non melanoma skin cancer in IBD patients before treatment with thiopurines and anti-TNFs: A prospective cohort study

Authors:

E. Lolli1, R. Saraceno2, C. Petruzziello1, G. Condino1, M. Ascolani1, A. Ventura2, A. Capanna1, A. Ruffa1, S. Onali1, E. Calabrese1, S. Chimenti2, F. Pallone1, L. Biancone1, 1Università di Roma Tor Vergata, Medicina dei sistemi, cattedra di Gastroenterologia, Roma, Italy, 2Dermatology Unit, University of Rome Tor Vergata, Systems Medicine, Rome, Italy

P352. Need for infliximab dose intensification in patients with Crohn's disease and ulcerative colitis
P352. Rates of hospitalization for inflammatory bowel diseases in Poland
P352. The effectiveness and safeness of allogeneic mesenchymal bone marrow stromal cells in patients with refractory Crohn's disease – 5 years of observation
Authors:

O. Knyazev1, P. Shcherbakov1, A. Parfenov1, I. Ruchkina1, A. Konoplyannikov2, L. Lazebnik3, 1Central Research Institute of Gastroenterology, Moscow, Russian Federation, 2Medical Radiological Research Center, Obninsk, Russian Federation, 3Clinical Hospital 33 of Moscow City, Moscow, Russian Federation

P352

Unblinded Results from a dose-escalating placebo-controlled study with allogeneic bone marrow-derived mesenchymal stem cells for the treatment of refractory perianal fistulas in patients with Crohn's disease

Authors:

I. Molendijk1, B.A. Bonsing2, H. Roelofs3, K.C. Peeters2, M.N. Wasser4, R.A. Veenendaal1, J.J. Zwaginga3, H.W. Verspaget1, W.E. Fibbe3, A.E. van der Meulen - de Jong*1, D.W. Hommes1, 5

1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Centre, Surgery, Leiden, Netherlands, 3Leiden University Medical Center, Immunohematology and Blood Transfusion, Leiden, Netherlands, 4Leiden University Medical Centre, Radiology, Leiden, Netherlands, 5University of California Los Angeles, Digestive Diseases, Los Angeles, United States

P353.

Screening for latent tuberculosis is effective but does not fully protect against tuberculosis reactivation during anti-TNF treatment in areas with high background incidence of tuberculosis

Authors:

Z. Zelinkova1, M. Zakuciova2, L. Gombosova2, E. Veseliny2, M. Horakova3, P. Lietava3, K. Palencikova3, B. Kadleckova4, M. Gregus5, K. Gregusova5, I. Pav6, T. Hlavaty1, T. Koller1, J. Toth1, M. Hlista7, I. Bunganic8, J. Zan9, I. Mincik9, M. Huorka1, 1University Hospital Bratislava, Gastroenterology Unit, 5th Department of Internal Medicine, Bratislava, Slovakia, 2University Hospital of Louis Pasteur, Gastroenterology Unit, 1st Department of Internal Medicine, Kosice, Slovakia, 3University Hospital, Department of Gastroenterology, Martin, Slovakia, 4Thalion, Gastroenterology & Hepatology Centrum, Bratislava, Slovakia, 5Gastroenterology and Hepatology Unit Nitra, GHU Nitra, Nitra, Slovakia, 6University Hospital, Gastroenterology Department, Bratislava, Slovakia, 7Medical Faculty Hospital, Gastroenterology Unit, Department of Internal Medicine, Trencin, Slovakia, 8Gastro I, Gastroenterology Center, Presov, Slovakia, 9Central Military Hospital, Gastroenterology Unit, Ruzomberok, Slovakia

P353. Influence of frozen food consumption in risk for developing inflammatory bowel disease
P353. MMX®, a mesalazine and long-term safety: A pooled analysis
P353. The economics of 4 grams once daily mesalazine dosing compared with 4 grams twice daily in active ulcerative colitis
Authors:

M. Connolly1, J. Kuyvenhoven2, M. Postma1, S. Nielsen3, 1University of Groningen, Department of Pharmacoeconomics and Pharmacoepidemiology, Groningen, Netherlands, 2Kennemer Gasthuis, Gastroenterology, Haarlem, Netherlands, 3Ferring International, Health Economics, St-Prex, Switzerland

P353

Are we under-recognizing skewed thiopurine metabolism in IBD patients? Routine thiopurine metabolite measurement yields clinical benefit at 12 months: A retrospective observational study.

Authors:

S.-Y.J. Ooi1, M. Gounder2, R. Grafton1, P. Leach3, A. Sechi2, W. Ng2, S. Connor2, P. Bampton3, J.M. Andrews*1

1Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia, 2Liverpool Hospital, Gastroenterology & Hepatology, Liverpool, Australia, 3Flinders Medical Centre, Inflammatory Bowel Disease Service, Bedford Park, Australia

P354.

Satisfaction and concerns about anti-TNF alpha therapy in Crohn's disease – the patient's perspective in a Portuguese population

Authors:

C. Fernandes, T. Pais, I. Ribeiro, R. Pinho, A.P. Silva, A. Rodrigues, L. Proença, L. Alberto, J. Carvalho, Gaia Hospital, Gastroenterology, Vila Nova Gaia, Portugal

P354. Surgery in first years after diagnosing IBD [on behalf of Dutch Delta IBD group]
P354. The bone mineral density in patients with inflammatory bowel disease (IBD), depending on clinical parameters of disease
Authors:

E. Belousova1, A. Dreval1, M. Turbina1, 1Moscow Regional Research Clinical Institute, Moscow, Russian Federation